For Roche, the future is personal. Fitting the treatment to the patient is an ambitious goal - but the concept of personalised healthcare is at the heart of our research and development strategy. Through this approach, we aim to use new molecular insights to provide more tailored medicines and enhance the management of anaemia.
Roche has a rich pipeline of new products, with global and UK based development teams managing international and local clinical trials working towards new treatments, including those for anaemia. Over 235,400 people took part in our clinical trials worldwide in 2008, receiving access to the latest therapies.
Ultimately, our goal is to use modern technologies to provide healthcare professionals with even more effective biopharmaceutical treatments based on new insights into how anaemia arises at the molecular level.